Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JNJ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- New False Claims Act Complaint (new) — A new False Claims Act complaint was filed against the Company and DePuy Synthes, alleging submission of false claims to federal and Florida healthcare programs.
Johnson & Johnson's second-quarter sales rose 6.6% to $25.31B, while net earnings of $5.53B included charges primarily related to talc matters.
Filed July 23, 2026 · Period ending June 28, 2026 · Compared to 10-Q Jul 24, 2025 · ~1 min read
Key Financials
SEC XBRL| Metric | PriorJun 29, 2025 | CurrentJun 28, 2026 | Δ |
|---|---|---|---|
| Revenue | $23.7B | $25.3B | ▲ +6.6% |
| Net income | $5.54B | $5.53B | ▼ -0.1% |
| Diluted EPS | $2.29 | $2.27 | ▼ -0.9% |
| Cash & equivalents | $18.6B | $20.4B | ▲ +9.9% |
| Long-term debt (noncurrent) | $39.2B | $37.3B | ▼ -4.8% |
| Total assets | $193.4B | $201.1B | ▲ +4.0% |
As reported in XBRL by the filer · 10-Q vs 10-Q. Income figures cover the fiscal quarter (not year-to-date); cash & assets are period-end balances. n/m = not meaningful (sign change; a % would mislead). about this table · verify on EDGAR →
Key Number Changes
Prior filing · verify on EDGAR →
As of the second quarter 2025, the total present value of the reserve is approximately $4.0 billion, comprising previously executed settlement agreements, litigation defense and other costs.
Current filing · verify on EDGAR →
As of the second quarter of 2026, the total present value of the reserve for talc related matters is approximately $3.7 billion, comprising executed settlement agreements, litigation defense and other costs.
Prior filing · verify on EDGAR →
Body powders containing talc, primarily JOHNSON’S Baby Powder 70,030
Current filing · verify on EDGAR →
As of June 28, 2026, there are approximately 76,000 plaintiffs in the United States with direct claims against the Company and its affiliates in pending lawsuits regarding injuries allegedly due to the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
Key Changes
-
high
Worldwide sales increased 6.6% to $25.31B in the fiscal second quarter, with Innovative Medicine sales up 7.8% to $16.38B.
-
high
Net earnings were $5.53B, essentially unchanged from $5.54B a year earlier, and included charges primarily related to talc matters; six-month net earnings fell 34.9% to $10.77B, also including talc-related charges.
-
medium
The company disclosed a new False Claims Act complaint against Johnson & Johnson and DePuy Synthes, alleging submission of false claims to federal and Florida healthcare programs.
-
medium
Cash flow from operations rose 38.2% to $11.13B in the first six months, and the company repurchased $4.25B of common stock.
-
medium
The company initiated a new supply chain restructuring program in Innovative Medicine with estimated costs of $650 million and $750 million and recorded $200.0M of restructuring expense in the segment.
Summary
Johnson & Johnson reported fiscal second quarter sales of $25.31B, up 6.6% from $23.74B a year earlier. Innovative Medicine sales grew 7.8% to $16.38B, while MedTech sales increased 4.5% to $8.93B. Net earnings were $5.53B, compared with $5.54B in the prior-year quarter, and included charges primarily related to talc matters.
Cash flow from operations was $11.13B in the first six months, up from $8.05B, and the company repurchased $4.25B of common stock.
The company disclosed a new False Claims Act complaint filed against Johnson & Johnson and DePuy Synthes in June 2026, alleging submission of false claims to federal and Florida healthcare programs. The company also initiated a new supply chain restructuring program in Innovative Medicine, with estimated costs between $650 million and $750 million and completion expected by the end of 2029.
Section-by-Section Diff
MD&A
The MD&A now discloses a new supply chain restructuring program in Innovative Medicine and the planned separation of the Orthopaedics business, while talc-related charges replace the prior year's reserve reversal.
Added in current filing · verify on EDGAR →
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million, and include site and supplier exit costs, decommissioning and asset impairments costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.
The Company initiated a new supply chain restructuring program in the Innovative Medicine segment, with estimated costs of $650-$750 million and completion expected by end of 2029. This is a new material program not present in the prior year.
Added in current filing · verify on EDGAR →
In October 2025, the Company announced its intention to separate its Orthopaedics business. The Company continues to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.
The Company announced its intention to separate the Orthopaedics business, a significant strategic change not disclosed in the prior year MD&A.
Added in current filing · verify on EDGAR →
Orthopaedics separation related costs of $0.4 billion in 2026
The MedTech segment incurred $0.4 billion in Orthopaedics separation related costs in the first half of 2026, a new expense category not present in the prior year.
Previous filing · verify on EDGAR →
The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be completed over the next two years.
Current filing · verify on EDGAR →
The estimated costs of the total program are between $0.6 billion - $0.7 billion and is expected to be substantially completed by the end of fiscal year 2026.
The estimated total cost of the Surgery franchise restructuring program was reduced from $0.9-$1.0 billion to $0.6-$0.7 billion, and the expected completion was accelerated to end of fiscal 2026.
Show 2 minor / wording changes
Previous filing · verify on EDGAR →
in June 2025, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 24, 2026)
Current filing · verify on EDGAR →
in June 2026, the Company secured a new 364-day Credit Facility of $12.5 billion (expiration on June 23, 2027)
The Company replaced its $10 billion credit facility with a larger $12.5 billion facility, increasing available liquidity.
Previous filing · view on EDGAR →
Russia-Ukraine war
Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal six months ending June 29, 2025, and the fiscal year ending December 29, 2024, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and represented approximately 1% of revenues. The Company does not maintain Ukrainian subsidiaries.
In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.
Conflict in the Middle East
Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2025, including accounts receivable or inventory reserves, was not material. As of the fiscal six months ending June 29, 2025, and the fiscal year ending December 29, 2024, the business of the Company’s Israel subsidiaries represented less than 1% of both Company’s consolidated assets and revenues.
Current filing · verify on EDGAR →
The long-term implications of regional conflicts on the Company are difficult to predict. The financial impact of known existing conflicts in the fiscal second quarter of 2026 was not material.
The detailed disclosures about the Russia-Ukraine war and Middle East conflict have been replaced with a generic statement about regional conflicts, reducing transparency on specific geopolitical exposures.
Legal Proceedings
Talc litigation reserve decreased and the talc plaintiff count rose, while new patent and False Claims Act litigation was disclosed.
Previous filing · verify on EDGAR →
As of the second quarter 2025, the total present value of the reserve is approximately $4.0 billion, comprising previously executed settlement agreements, litigation defense and other costs.
Current filing · verify on EDGAR →
As of the second quarter of 2026, the total present value of the reserve for talc related matters is approximately $3.7 billion, comprising executed settlement agreements, litigation defense and other costs.
The talc reserve decreased from $4.0 billion to $3.7 billion.
Previous filing · verify on EDGAR →
Body powders containing talc, primarily JOHNSON’S Baby Powder 70,030
Current filing · verify on EDGAR →
As of June 28, 2026, there are approximately 76,000 plaintiffs in the United States with direct claims against the Company and its affiliates in pending lawsuits regarding injuries allegedly due to the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
The number of talc plaintiffs increased from 70,030 to approximately 76,000.
Previous filing · verify on EDGAR →
On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case (the Texas dismissal) and, as a result, the Company reversed substantially all, or approximately $7 billion, from amounts previously reserved for the bankruptcy resolution.
Current filing · verify on EDGAR →
In connection with these restructurings, the Company filed a series of three Chapter 11 bankruptcy proceedings. Ultimately, each of the bankruptcy proceedings was dismissed and, as a result, the Company reversed substantially all, or approximately $7.0 billion, from amounts previously reserved for the bankruptcy resolution in the fiscal first quarter of 2025.
The current filing states that all three Chapter 11 bankruptcy proceedings were dismissed, whereas the baseline described only the Texas dismissal.
Previous filing · verify on EDGAR →
Courts have begun to hold scheduling conferences and the Company is preparing to start bellwether trials in consolidated proceedings in the California JCCP in November 2025 and in the New Jersey MCL in January 2026.
Current filing · verify on EDGAR →
In the ovarian cancer multi-district litigation (MDL) in the United States District Court for the District of New Jersey, the court is addressing the Company's Daubert motions related to general causation, specific causation, and certain asbestos testing methods.
The current filing provides detailed updates on Daubert motions in the ovarian cancer MDL, including a Special Master's report and the withdrawal of plaintiff experts, which were not present in the baseline.
Previous filing · verify on EDGAR →
Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.
Current filing · verify on EDGAR →
In February 2026, the Company filed a writ of certiorari with the United States Supreme Court regarding the Third Circuit’s decision, which the Supreme Court denied in April 2026. Expert discovery is proceeding.
The securities class action has progressed: the Third Circuit affirmed class certification, the Supreme Court denied certiorari, and expert discovery is now proceeding.
Previous filing · verify on EDGAR →
The briefing of the Settlement Order appeal in the Delaware District Court was completed in April 2025, and the appeal is pending a decision from the Court.
Current filing · verify on EDGAR →
In August 2025, the district court denied the insurers' appeal of the Settlement Order. The insurers have appealed that decision to the Third Circuit. Briefing in the Third Circuit appeal is complete and a ruling is pending.
The district court denied the insurers' appeal, and the insurers have now appealed to the Third Circuit, where briefing is complete and a ruling is pending.
Added in current filing · verify on EDGAR →
In January 2026, 2seventy bio, Inc. filed suit in the Unified Patent Court, Local Division of Brussels, against the Company, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag NV, Janssen Biologics B.V., Janssen-Cilag B.V., Janssen-Cilag GmbH, Janssen-Cilag, Janssen-Cilag SpA, Janssen-Cilag A/S, Janssen-Cilag Aktiebolag, Janssen-Cilag Farmaceutica Lda., Legend Biotech Corporation, Legend Biotech USA Inc., Legend Biotech Ireland Limited, and Legend Biotech Belgium BV alleging that the manufacture and sale of CARVYKTI infringes EU Patent No. 3 689 383.
A new patent infringement suit was filed against the Company and its partners regarding CARVYKTI, alleging infringement of an EU patent.
Added in current filing · verify on EDGAR →
In June 2026, three Relators filed an Amended False Claims Act Complaint in the United States District Court for the Southern District of Florida alleging the Company and DePuy Synthes, along with Tenet Healthcare Corporation, Delray Medical Center, and West Boca Medical Center caused the submission of false claims to federal and Florida healthcare programs.
A new False Claims Act complaint was filed against the Company and DePuy Synthes, alleging submission of false claims to healthcare programs.
Notes
Johnson & Johnson initiated a new supply chain restructuring program in Innovative Medicine and disclosed new litigation, including a False Claims Act complaint.
Added in current filing · verify on EDGAR →
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million, and include site and supplier exit costs, decommissioning and asset impairments costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.
The Company launched a new restructuring program in Innovative Medicine, with estimated costs of $650-$750 million and $200 million recorded in Q2 2026.
Previous filing · verify on EDGAR →
Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be completed over the next two years.
Current filing · verify on EDGAR →
Total project costs of approximately $0.3 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.6 billion - $0.7 billion and is expected to be substantially completed by the end of fiscal year 2026.
The estimated total cost of the Surgery franchise restructuring program was reduced from $0.9-$1.0 billion to $0.6-$0.7 billion, and the expected completion date was moved up to the end of fiscal 2026. This indicates lower expected restructuring charges.
Previous filing · verify on EDGAR →
Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be substantially completed by the end of fiscal year 2025.
Current filing · verify on EDGAR →
Total project costs of approximately $0.8 billion have been recorded since the restructuring was announced. This program will be completed as of the fourth quarter of 2026 at a total cost of approximately $1.0 billion.
The estimated total cost of the Orthopaedics franchise restructuring program increased from $0.7-$0.8 billion to approximately $1.0 billion, and the completion date was extended to the fourth quarter of 2026. This indicates higher expected restructuring charges.
Added in current filing · verify on EDGAR →
In June 2026, three Relators filed an Amended False Claims Act Complaint in the United States District Court for the Southern District of Florida alleging the Company and DePuy Synthes, along with Tenet Healthcare Corporation, Delray Medical Center, and West Boca Medical Center caused the submission of false claims to federal and Florida healthcare programs. The Relators are sales representatives for competitor companies, and the complaint was served following a decision by the Department of Justice to decline intervening in the case. The Company and DePuy Synthes disagree with and are defending themselves against these claims.
A new False Claims Act complaint was filed against the Company and DePuy Synthes in June 2026. The DOJ declined to intervene, but the relators are pursuing the case.
Added in current filing · verify on EDGAR →
In January 2026, 2seventy bio, Inc. filed suit in the Unified Patent Court, Local Division of Brussels, against the Company, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag NV, Janssen Biologics B.V., Janssen-Cilag B.V., Janssen-Cilag GmbH, Janssen-Cilag, Janssen-Cilag SpA, Janssen-Cilag A/S, Janssen-Cilag Aktiebolag, Janssen-Cilag Farmaceutica Lda., Legend Biotech Corporation, Legend Biotech USA Inc., Legend Biotech Ireland Limited, and Legend Biotech Belgium BV alleging that the manufacture and sale of CARVYKTI infringes EU Patent No. 3 689 383. In the suit, the exclusive licensee, 2seventy bio, Inc., seeks damages and an injunction.
A new patent infringement lawsuit was filed against the Company and its subsidiaries regarding CARVYKTI in the Unified Patent Court. The plaintiff seeks damages and an injunction.
Added in current filing · verify on EDGAR →
In March 2026, Janssen Biotech, Inc. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Accord BioPharma, Inc. (Accord) and Bio-Thera Solutions, Ltd. in response to Accord’s filing of an aBLA seeking approval to market biosimilar versions of SIMPONI and SIMPONI ARIA and providing notice of commercial marketing pursuant to 42 U.S.C. § 262(l) (8) (A) for those biosimilar products.
The Company initiated a new patent infringement lawsuit to protect SIMPONI and SIMPONI ARIA from biosimilar competition.
Previous filing · verify on EDGAR →
In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.
Current filing · verify on EDGAR →
In October 2020, Fortis Advisors LLC, as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company alleging breach of contract, fraud, and other causes of action in connection with Ethicon’s acquisition of Auris in 2019. In January 2026, the Company paid a $0.8 billion judgment, inclusive of interest.
The Fortis Advisors litigation was resolved with a $0.8 billion payment in January 2026, compared to the prior period where the Company was appealing the decision. This is a significant cash outflow and removes an uncertainty.
Previous filing · verify on EDGAR →
In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.
Current filing · verify on EDGAR →
In February 2026, the parties agreed to settle the matter. In July 2026, the court granted final approval of the settlement.
The TRACLEER antitrust class action was settled and received final court approval in July 2026, whereas previously a trial was scheduled for March 2026. This removes a litigation uncertainty.
Controls
The Company resumed open-market share repurchases in the fiscal second quarter of 2026 after none in the prior year period.
Previous filing · verify on EDGAR →
During the fiscal second quarter of 2025, the Company did not repurchase any shares of Johnson & Johnson Common Stock in open-market transactions.
Current filing · verify on EDGAR →
During the fiscal second quarter of 2026, the Company repurchased an aggregate of 970,250 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company’s compensation programs.
The Company resumed open-market share repurchases in the fiscal second quarter of 2026, buying 970,250 shares for compensation programs, after no repurchases in the prior year period.
Financial Statements
Primary statements as printed on the EDGAR filing (iXBRL face). Companyfacts is used only when a statement is not on the HTML face. Not generated by the model.
Consolidated Statements of Operations (Unaudited)
(in millions, except per share amounts; mapped from filer XBRL tags, not printed on the filing face)
| Description | Q2 ended Jun 28, 2026 | Q2 ended Jun 29, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 25,310 | 23,743 |
| Cost of revenue / cost of sales | 8,051 | 7,628 |
| Gross profit | 17,259 | 16,115 |
| Operating expenses: | ||
| Research and development | 3,653 | 3,516 |
| Selling, general and administrative | 6,432 | 5,889 |
| Interest expense | 281.0 | 308.0 |
| Other income/(expense), net | (331.0) | (107.0) |
| Income before income taxes | 6,747 | 6,491 |
| Income tax expense/(benefit) | 1,213 | 954.0 |
| Net income | 5,534 | 5,537 |
| Basic earnings per share | 2.30 | 2.30 |
| Diluted earnings per share | 2.27 | 2.29 |
consolidated balance sheets (Unaudited)
(Unaudited; Dollars in Millions Except Share and Per Share Data)
| Description | June 28, 2026 | December 28, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents (Note 4) | 20,422 | 19,709 |
| Marketable securities | 336 | 393 |
| Accounts receivable, trade, less allowances $171 (2025, $183) | 19,046 | 17,178 |
| Inventories (Note 2) | 15,144 | 14,191 |
| Prepaid expenses and other | 4,826 | 4,153 |
| Total current assets | 59,774 | 55,624 |
| Property, plant and equipment at cost | 55,518 | 54,364 |
| Less: accumulated depreciation | (31,936) | (31,195) |
| Property, plant and equipment, net | 23,582 | 23,169 |
| Intangible assets, net (Note 3) | 48,229 | 50,403 |
| Goodwill (Note 3) | 48,479 | 48,772 |
| Deferred taxes on income (Note 5) | 6,728 | 6,874 |
| Other assets | 14,269 | 14,368 |
| Total assets | 201,061 | 199,210 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Loans and notes payable | 11,692 | 8,495 |
| Accounts payable | 9,223 | 11,991 |
| Accrued liabilities | 9,464 | 8,594 |
| Accrued rebates, returns and promotions | 19,990 | 19,124 |
| Accrued compensation and employee related obligations | 3,475 | 4,534 |
| Accrued taxes on income (Note 5) | 1,051 | 1,388 |
| Total current liabilities | 54,895 | 54,126 |
| Long-term debt (Note 4) | 37,344 | 39,438 |
| Deferred taxes on income (Note 5) | 6,608 | 6,791 |
| Employee related obligations (Note 6) | 6,657 | 6,957 |
| Long-term taxes payable (Note 5) | 485 | 486 |
| Other liabilities | 10,101 | 9,868 |
| Total liabilities | 116,090 | 117,666 |
| Commitments and Contingencies (Note 11) | ||
| Shareholders’ equity: | ||
| Common stock par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 7) | (13,951) | (14,930) |
| Retained earnings and Additional paid-in capital | 171,665 | 168,978 |
| Less: common stock held in treasury, at cost (711,615,000 and 711,904,000 shares) | 75,863 | 75,624 |
| Total shareholders’ equity | 84,971 | 81,544 |
| Total liabilities and shareholders’ equity | 201,061 | 199,210 |
consolidated statements of cash flows (Unaudited)
(Unaudited; Dollars in Millions)
| Description | Fiscal six months ended June 28, 2026 | Fiscal six months ended June 29, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net earnings | 10,769 | 16,536 |
| Adjustments to reconcile net earnings to cash flows from operating activities: | ||
| Depreciation and amortization of property and intangibles | 3,963 | 3,715 |
| Stock based compensation | 758 | 698 |
| Asset write-downs | 220 | 30 |
| Charges for acquired in-process research and development assets | 2 | 92 |
| Net loss/(gain) on sale of assets/businesses | (43) | (74) |
| Deferred tax provision | (320) | 2,997 |
| Credit losses and accounts receivable allowances | (12) | 3 |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | ||
| Increase in accounts receivable | (1,947) | (2,283) |
| Increase in inventories | (1,002) | (656) |
| Decrease in accounts payable and accrued liabilities | (956) | (886) |
| Decrease/(Increase) in other current and non-current assets | 1,299 | (6,194) |
| Decrease in other current and non-current liabilities | (1,601) | (5,926) |
| Net cash flows from operating activities | 11,130 | 8,052 |
| Cash flows used for investing activities | ||
| Additions to property, plant and equipment | (2,370) | (1,838) |
| Proceeds from the disposal of assets/businesses, net (Note 10) | 92 | 332 |
| Acquisitions, net of cash acquired (Note 10) | (263) | (14,458) |
| Acquired in-process research and development assets / related milestones (Note 10) | — | (369) |
| Purchases of investments | (299) | (431) |
| Sales of investments | 368 | 953 |
| Credit support agreements activity, net | 515 | (2,684) |
| Other (including capitalized licenses and milestones) | (193) | (66) |
| Net cash used for investing activities | (2,150) | (18,561) |
| Cash flows (used for) from financing activities | ||
| Dividends to shareholders | (6,358) | (6,118) |
| Repurchase of common stock | (4,249) | (2,127) |
| Proceeds from short-term debt, net | 13,146 | 9,349 |
| Repayment of short-term debt, net | (9,677) | (5,058) |
| Proceeds from long-term debt, net of issuance costs | — | 9,138 |
| Repayment of long-term debt | (2,003) | (754) |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 1,531 | 557 |
| Credit support agreements activity, net | (49) | (271) |
| Other | (588) | 41 |
| Net cash (used for) from financing activities | (8,247) | 4,757 |
| Effect of exchange rate changes on cash and cash equivalents | (20) | 224 |
| Increase in cash and cash equivalents | 713 | (5,528) |
| Cash and cash equivalents, beginning of period | 19,709 | 24,105 |
| Cash and cash equivalents, end of period | 20,422 | 18,577 |
Face scale: (Unaudited; Dollars in Millions Except Share and Per Share Data); (Unaudited; Dollars in Millions). Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags, at the scale noted on each table. EPS as reported. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 24, 2026 · How we verify